Purpose An effective method for controlling haemostasis during open thyroidectomy procedures is crucial because of the high risks of haemorrhage and neck haematoma. This study aimed to demonstrate the efficacy of the integrated ultrasonic/ bipolar Thunderbeat™ for this procedure. Methods This retrospective non-inferiority study compared the Thunderbeat™ and the ultrasonic Harmonic Focus® devices in 761 consecutive patients receiving a partial or total open thyroidectomy (with or without neck dissection). The main outcomes were duration of surgery, blood loss, and length of hospitalisation. Secondary outcomes were occurrence of hypocalcaemia, recurrent nerve paralysis, or other post-operative complications. A non-inferiority logistic regression approach was used to evaluate primary outcomes, adjusting for age, gender, body mass index, type of surgery, anaesthesiology score, and indication (benign or malign). Results The data demonstrated that the Thunderbeat was noninferior to the Focus in terms of duration of surgery, blood loss, and length of hospital stay. Furthermore, subgroup analyses showed non-inferiority of the Thunderbeat for partial thyroidectomy (all three outcomes), total thyroidectomy (duration of surgery and length of hospitalisation), and total thyroidectomy with neck dissection (length of hospitalisation). In terms of recurrent nerve paralysis and post-operative complications, the Thunderbeat performed at least as well as the Focus; however, no conclusions could be drawn regarding the occurrence of post-operative hypocalcaemia. Conclusion In a cohort of patients that underwent partial or total thyroidectomy, the Thunderbeat appeared to be at least as good as the Harmonic Focus.
Introduction
The thyroid gland is a highly vascularised organ located in close proximity to the parathyroid glands and the laryngeal nerves. Therefore, a reliable and effective method for achieving haemostasis is essential to prevent complications such as haemorrhage or neck haematoma and to maintain a clear view of the surgical field to preclude damage to surrounding tissues. This latter point is particularly pertinent to thyroid surgery because of the narrow operating field [1] [2] [3] [4] [5] . Furthermore, minimisation of blood loss and post-operative complications is important not only for the well-being of patients but also for cost-effectiveness [3, 6, 7] .
Over the last two decades, instruments that utilise novel energy sources for achieving surgical haemostasis have been introduced [8, 9] , including advanced bipolar clamps that allow coagulation of blood vessels up to 7 mm in diameter with heat production maintained at <100°C [10, 11] . A more recent innovation is the use of ultrasound, providing a product that enables simultaneous cutting and sealing and generates lower temperatures (60 to 80°C) in comparison to bipolar energy. However, after prolonged activation (>10 s) or at high power settings (levels 4 and 5), ultrasonic energy has the drawback of reaching temperatures of >100°C, meaning that adjacent tissues are susceptible to injury [12] [13] [14] .
The most widely used haemostasis devices for thyroid surgery are the advanced bipolar LigaSure™ clamp (Covidien, Boulder, CO, USA) and the ultrasonic Harmonic Focus® scalpel with curved shears (Ethicon Endo-Surgery, Cincinnati, OH, USA) [9, 15] . These devices have been associated with reductions in both the cost and duration of surgery, as well as complication rates [2, 16, 17] . Nevertheless, because advanced bipolar energy is not suitable for cutting and dissecting tissue, and ultrasonic energy produces high temperatures following prolonged activation, it may be hypothesised that an improved device should combine the advantages of both types of energy [18, 19] . Comparative studies of the LigaSure™ versus the Focus for thyroidectomy report varied results, with no clear and consistent benefit of one energy source over the other [15, 17, [20] [21] [22] [23] . Following on from energy-based surgical devices that rely upon a single type of energy, the Thunderbeat™ (Olympus, Japan) combines ultrasonic energy for cutting tissue with advanced bipolar energy for coagulation. The Thunderbeat has been available since 2012 and facilitates cutting and sealing of blood vessels up to 7 mm in diameter in a single step [24] .
To date, clinical evaluation of the Thunderbeat has been performed in patients undergoing minimally invasive visceral or gynaecological procedures [25] [26] [27] . The aim of the present study was to compare the efficacy and safety of the Thunderbeat with the Focus in a cohort of consecutive patients who underwent an open thyroidectomy.
Methods

Study design
This was a retrospective clinical study based on prospectively collected data, which assessed the use of the Thunderbeat and the Harmonic Focus for open thyroidectomy. The single centre study was conducted from September 2009 to October 2014. Ethical approval was obtained from the ethics committee of the Onze-Lieve Vrouw (OLV) Clinic Aalst, and all patients provided written informed consent. Neither financial support nor any free devices were received from the industry.
Patients and exposure
All consecutive patients who underwent either complete or partial thyroidectomy with or without lymph node clearance were enrolled. The same experienced surgeon performed all procedures. The procedures differed only in the instrument used.
The Harmonic Focus system comprises a range of ultrasonic surgical devices that enable simultaneous dissection and coagulation of tissue. Ultrasonic waves are created by electromagnetic energy from a generator, which undergoes piezoelectric transduction within the hand piece. The blade of the Harmonic scalpel vibrates at 55 kHz, producing mechanical energy that breaks hydrogen bonds. The Harmonic Focus is hand-activated, with cutting and sealing of vessels achieved by placing the curved blade in contact with the tissue and applying pressure [28] .
The Thunderbeat device integrates ultrasonic energy for dissection with advanced bipolar energy that coagulates tissue by denaturing collagen and elastin to form a seal. It is composed of an upper bipolar jaw and a lower ultrasonic and bipolar probe which facilitates two functional modes: seal and cut for vessel sealing and coagulation with simultaneous cutting, and a seal mode for coagulation alone [24] . Throughout the whole procedure, no haemostatic agents other than the energy devices were used; no ligatures or clips were applied in the dissection of the nerves or parathyroids.
The first enrolled patients were all operated on with the Focus. The Thunderbeat was gradually introduced from May 2012 and was used in the majority of cases in 2013-2014.
Diagnostics and treatment
At baseline (before surgery), levels of thyroid-stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), calcium, calcitonin, and thyroglobulin were measured, and all patients underwent ultrasonography and scintigraphy to visualise the thyroid pathology. When clinically relevant, a CT scan was performed, and biopsies were taken for fine needle aspiration and Bethesda classification of suspected or confirmed malignancies. Intraoperative neuromonitoring of the laryngeal nerves, in addition to continuous vagal nerve monitoring, was routinely performed in all patients [29, 30] . Following surgery, the presence of hypocalcaemia was documented, parathyroid hormone (PTH) levels were recorded at 4 h, and calcium levels were recorded on days 1 and 2. All patients received daily doses of levothyroxine (LT4) ranging from 25 to 200 μg. Patients were discharged from hospital, and followup was conducted on site at 6 weeks post-surgery. Patients with hypocalcaemia lasting for over 6 weeks were monitored until recovery of parathyroid function was achieved. Nerve injury/vocal cord assessment was performed using routine laryngoscopy during a pre-operative surgical visit and at 1 day after surgery. Patients with recurrent paralysis were monitored by laryngoscopy every 3 months until they had regained mobility, or up to a year after surgery, which is the time at which permanent palsy is diagnosed.
Outcomes
Our main outcomes compared the efficacy of both tools, measured as duration of surgery from skin incision to skin closure (in minutes), intraoperative volume of blood loss (in mL), and length of hospital stay (in days). Our secondary outcomes considered safety: post-operative temporary hypocalcaemia (present or absent, defined as PTH <15 ng/L at 4 h after the operation), post-operative transient recurrent nerve paralysis (present or absent), and other post-operative complications defined according to the Clavien-Dindo system (categorised as no complications-Clavien score 0; or complicationsClavien score 1-3) [31] . Post-operative hypocalcaemia was only evaluated for patients receiving a total thyroidectomy (with or without neck dissection). Permanent hypocalcaemia was defined as a need for vitamin D or calcium supplementation 1 year after surgery. Permanent recurrent nerve paralysis was defined as paralysis still present 1 year after surgery.
Potential confounders
For this study, data were collected on the following potential confounders: age (categorised into three groups: 19-39 years, 40-59 years, and 60-90 years), gender (male or female), body mass index (BMI; categorised into four groups: <20, 20.0-24.9, 25.0-29.9, and ≥30 kg/m 2 ), the American Society of Anesthesiologists (ASA) score (categorised into four groups: fit and healthy (I), mild systemic disease (II), severe systemic disease (III), and incapacitating or life-threatening systemic disease (IV) [32] ), indication for surgery (malign or benign), and type of surgery (partial thyroidectomy, total thyroidectomy, or total thyroidectomy with neck dissection).
Statistical analysis
Descriptive statistics are presented as median and interquartile ranges (IQRs) or as number of patients and proportions (%). Complete-case univariate and multivariate linear and logistic regression models were used to assess respectively the primary and secondary outcomes for both devices. The multivariable models were adjusted for the five potential confounders described above and the type of surgery (partial thyroidectomy, total thyroidectomy, or total thyroidectomy + neck dissection). The associations found by using linear regression models are presented as coefficients and 95 % confidence intervals (CIs), with the Focus as the reference group. The logistic regression models are presented as odds ratios (ORs) and 95 % CI, also with the Focus as the reference group. Stratified analyses were used to evaluate the three primary outcomes for each type of surgery.
In order to determine if any differences in the performance of the two devices were clinically relevant [33] , we a priori defined Bminimum important differences.^For the primary outcomes, a decrease of 10 min duration of surgery, 15 mL less blood loss, and 1 day shorter hospitalisation were considered clinically relevant. For the secondary outcomes, decreases of 10 % in the number of patients with hypocalcaemia, recurrent nerve paralysis, or other post-operative complications were considered clinically relevant. To analyse these differences, we employed a one-sided equivalence approach [34, 35] . The null hypothesis stated that the outcome values were larger than the minimum important differences in favour of the Focus, i.e. the Thunderbeat was inferior to the Focus. A p value <0.05 indicated that the Thunderbeat was not inferior to the Focus.
All analyses were performed using STATA (Stata Corporation, version 12).
Results
Patients
This study enrolled a total of 761 consecutive patients who underwent partial or total thyroidectomy or total thyroidectomy with neck dissection. The patient characteristics are presented in Table 1 . The Thunderbeat was used in more partial thyroidectomies compared to the Focus (33.9 versus 24.9 %). No major differences were seen in age, gender, BMI, and indication (benign or malign), yet more patients in the Focus group were considered healthy compared to the Thunderbeat group (23.7 and 12.3 % respectively).
The distributions of the primary outcomes are shown in Table 1 . Based on the median values and interquartile ranges, there were no major differences in duration of surgery, volume of blood loss, and length of hospitalisation. Overall, the median duration of surgery was 60 min (IQR 45-75 min) in the Focus group and 60 min (IQR 45-70 min) in the Thunderbeat group. The volume of blood loss was 14 mL (IQR 6-32 mL) in the Focus group and 14 mL (6-30 mL) in the Thunderbeat group, and the length of hospitalisation was 1 day (IQR 1-1) in both groups. For the subgroup of patients receiving total thyroidectomy with neck dissection, the median duration of surgery was slightly longer in patients operated on with the Focus compared to the Thunderbeat.
For the subgroup of patients receiving a total thyroidectomy, temporary hypocalcaemia was found in 34.9 and 40.9 % of all patients operated on with the Focus and Thunderbeat, respectively, with only 1.7 % in total with permanent hypocalcaemia.
Overall, transient recurrent nerve paralysis occurred in 6.3 % of patients in the Focus group and 2.3 % in the Thunderbeat group. Only three of these cases (two in Focus group, one in Thunderbeat) showed permanent damage. Clavien scores were comparable in both groups, with 78.9 and 84.4 % of all patients having no complications in the Focus and Thunderbeat groups, respectively.
Focus versus Thunderbeat
The results of the linear regression models are presented in Table 2 . The unadjusted (crude) model showed a 7.2-min shorter duration of surgery for patients operated on with the Thunderbeat compared to the Focus (95 % CI −12.9 to −1.6 min; p = 0.012). After adjustment, the difference became smaller and non-significant (−3.7 min; 95 % CI −8.5 to 1.0 min; p = 0.123). The test for clinical significance showed that the Thunderbeat was non-inferior to the Focus (p < 0.001).
For the volume of blood loss, no statistically significant differences were found between the Focus and Thunderbeat in both the unadjusted and multivariate models, with respective coefficients of 1.5 mL more blood ASA American Society of Anaesthesiologists, IQR interquartile range a Defined as parathyroid hormone 4 h post-operatively <15 ng/L (only patients receiving total thyroidectomy) loss for the Thunderbeat (95 % CI −11.6 to 14.6 mL; p = 0.818) and 2.0 mL less blood loss (95 % CI −14.8 to 10.8 mL; p = 0.758). These differences were not considered to be clinically relevant (p = 0.044 and 0.005 for unadjusted and adjusted, respectively), showing again that the Thunderbeat was non-inferior to the Focus. No statistically significant differences in length of hospital stay were found between the Focus and Thunderbeat in both the unadjusted and adjusted models, with a slightly shorter length of stay for the Thunderbeat of 0.2 days (95 % CI −0.5 to 0.1 days; p = 0.137) after adjustment. However, in terms of the clinical relevance of the length of hospital stay, non-inferiority of the Thunderbeat was found for both the unadjusted (p < 0.001) and adjusted models (p < 0.001).
The data therefore demonstrate that for the total population, the Thunderbeat was not inferior to the Focus at a clinically relevant level with regard to each of the three primary outcomes.
Subgroup analyses per type of surgery
The stratified, adjusted models for each type of surgery are presented in Table 3 . For partial thyroidectomy, the data demonstrated no statistically significant differences in duration of surgery (−0.5 min; 95 % CI −7.0 to 6.1; p = 0.893), volume of blood loss (2.2 mL; 95 % CI −2.4 to 6.8; p = 0.180), or length of hospital stay (0.0 days; 95 % CI −0.2 to 0.2; p = 0.258) for the Thunderbeat in comparison to the Focus. Considering clinical relevance, the Thunderbeat was found to be noninferior to the Focus for duration of surgery (p < 0.001), volume of blood loss (p < 0.001), and length of hospitalisation (p < 0.001).
Similarly, for total thyroidectomy, no statistically significant differences were found between the two devices, with a 3.1 min shorter duration of surgery when the Thunderbeat was used (95 % CI −7.6 to 1.4; minutes; p = 0.350), 2.2 mL less blood loss (95 % CI −20.5 to 16.2 mL; p = 0.818), and a 0.1-day shorter length of hospitalisation (95 % CI −0.4 to 0.2 days; Only calculated for patients with total thyroidectomy (with or without neck dissection), defined as parathyroid hormone <15 ng/L at 4 h post-operative p = 0.333). Clinically, the Thunderbeat was considered noninferior to the Focus when considering duration of surgery (p < 0.001) and length of hospitalisation (p < 0.001), with borderline significance found for blood loss (p = 0.068). In the small group of patients who underwent total thyroidectomy with neck dissection, no statistically significant differences were found for any of the three primary outcomes, yet we found a 39.3-min shorter duration of surgery (95 % CI −108.6 to 30.1 min; p = 0.892), 28.7 mL increased blood loss (95 % CI −31.2 to 88.6 mL; p = 0.386), and a 3.1-day shorter hospital stay (95 % CI −7.5 to 1.4 days; p = 0.171) for the Thunderbeat compared to the Focus. Considering clinical relevance, the Thunderbeat was considered non-inferior to the Focus in terms of length of hospital stay (p = 0.035), while differences in duration of surgery (p = 0.079) and volume of blood loss (p = 0.386) were not significant.
Post-operative complications
The adjusted OR for temporary hypocalcaemia of 1.33 (95 % CI 0.90 to 1.91; p = 0.132) shows that the risk of experiencing this was higher in patients operated on with the Thunderbeat in comparison to the Focus, albeit with a wide 95 % CI (Table 2b) . However, the difference was not found to be clinically relevant for noninferiority (p = 0.022).
Considering transient recurrent nerve paralysis, the adjusted OR of 0.31 (95 % CI 0.13 to 0.75; p = 0.009) shows a statistically significantly decreased risk in the Thunderbeat group compared to the Focus group. This difference was also considered to be clinically relevant, indicating that the Thunderbeat is not inferior to the Focus (p = 0.008).
The adjusted OR for other post-operative complications, as defined by the Clavien score, was 0.71 (95 % CI 0.47 to 1.06; p = 0.089), providing some evidence for a reduced risk of complications in the Thunderbeat group, although not statistically significant (p = 0.109 for noninferiority).
Discussion
This study has shown that the Thunderbeat is at least as good as the Focus when duration of surgery, volume of blood loss, and length of hospitalisation are compared in patients receiving open thyroidectomy. The Thunderbeat also performed at least as well as the Focus when the risk of transient recurrent nerve paralysis was compared, with even a statistically significant lower risk of transient recurrent nerve paralyses indicated.
The main strength of this study is that it is the first time that the Thunderbeat has been compared to other haemostasis devices in a large population undergoing open thyroidectomy. The same, highly experienced surgeon operated on all patients, so the impact of a learning curve should be negligible. Furthermore, there were no significant changes in practice during the study period.
However, this study also has some limitations, the main one being that this is not a randomised controlled trial, but a clinical trial including all consecutive patients operated on with the Focus and Thunderbeat during the study period. However, the differences between the patient characteristics and indications of the two device groups were small, and all analyses were adjusted for the major potential confounders. Although no factors, except for year of surgery, are known to have influenced the decision to use the Focus or Thunderbeat, unknown confounding issues could not be ruled out entirely. Nevertheless, this study is a real-life trial, comparing the effectiveness of both devices, which did not exclude patients based on indication, age, or comorbidity. In contrast, randomised controlled trials compare efficacy in highly selected, ideal populations. These data should be considered in the context that the Thunderbeat is a newer device that was not used by surgeons prior to 2012, whereas the Focus with curved shears has been in use since 2010 [28] . Furthermore, while the Focus was specifically designed for otolaryngological surgery [28] , the Thunderbeat has potential applications in a wide range of surgical procedures, in particular, laparoscopic procedures involving the abdomen or pelvis [25] [26] [27] . A clinical trial in patients with endometrial or cervical cancer demonstrated that, compared with monopolar scissors, the Thunderbeat reduced the duration of surgery and was associated with less post-operative pain and use of analgesia [25] .
Specifically for thyroid surgery, irreversible damage to the laryngeal nerves and permanent hypocalcaemia represent the most severe complications following thyroidectomy [4, 6] . In this study, we showed that the Thunderbeat was at least as good as the Focus in terms of the prevention of transient recurrent nerve paralysis and temporary hypocalcaemia. Yet, the risk of permanent damage to the recurrent nerve was very low (0.04 % in Focus group, 0.03 % in Thunderbeat group). Other clinical studies of open total thyroidectomy have suggested that the frequency of transient recurrent laryngeal nerve injury with the Focus ranges between 0.7 and 5.6 % [23] . The value of 6.3 % found in the present study for the frequency of recurrent nerve injury after total thyroidectomy is at the upper end of this spectrum, which may be due to our thorough screening and sensitive methods for detection. Even small deviations of vocal cords were picked up due to the neuromonitoring values where an eventual malfunctioning could be suspected. Moreover, this rate is high because of the early laryngoscopy, which was performed on the first post-operative day. The longer the delay before checking the vocal cords, the less palsy will be diagnosed. The lower proportion of patients with recurrent laryngeal nerve damage in the Thunderbeat group is surprising given the results of recent studies in porcine thyroidectomy models. Using a continuous neuromonitoring technique and device activation times of 10 s, Kwak et al. found no detectable electromyography events up to a distance of 3 mm from the recurrent laryngeal nerve for the Thunderbeat [36] , while Wu et al. found this to be true up to a distance of 1 mm for the Focus [37] . Furthermore, the latter study only detected events at 0 mm for activation times over 3 s [37] . While both studies suggest reasonable thermal spreads for use near to the laryngeal nerve, they also imply that a lower rate of laryngeal nerve injury may be expected when using the Focus, which was not the case in the present study. Possible reasons for this disparity are that both porcine studies had small sample sizes, the activation times studied may be shorter than those used clinically, and animal model findings may not translate into humans. Further investigation using larger samples and providing direct comparisons between devices are necessary to better clarify thermal spread in laryngeal tissue.
With respect to transient hypocalcaemia, published literature on the use of the Focus for total thyroidectomy demonstrates that the frequency varies widely (0 to 60 %) [23] , with rates in the present study being relatively low for both devices. However, these findings are likely to be dependent on the regimen of calcium supplementation, and in addition, it has been reported that the susceptibility of patients to developing hypocalcaemia is affected by indication (e.g. a higher incidence among patients with autoimmune thyroid disease) [38] . Therefore, we used a rather sensitive definition, based on PTH levels 4 h after surgery. The proportion of patients with permanent hypocalcaemia, and therefore a need for vitamin D or calcium supplementation 1 year after surgery, was less than 2 %.
Future studies are necessary to better distinguish between the utility of the Thunderbeat and the Focus devices for thyroidectomy. This may be achieved by comparing their safety and efficacy profiles for open versus minimally invasive thyroidectomies, as well as for different indications for the surgery, taking into account varying patient characteristics. Compared with first-generation electrosurgical devices, advanced bipolar and ultrasonic instruments have already yielded substantial improvements in the duration of surgery and amount of blood loss. With this in mind, it may be questionable whether any further reduction would translate into a clinically or economically relevant change. For example, the cost savings associated with a shorter procedure will only be substantial in hospitals that perform a large volume of thyroid surgeries, which is not the case for the majority of institutions [39] . Thus, when comparing haemostasis instruments, it may be of greater interest to focus on costeffectiveness or patient-related outcomes such as the size of incision, post-operative pain, hypocalcaemia, and recurrent nerve paralysis.
To conclude, this study demonstrates evidence that the Thunderbeat performs at least as well as the Focus during open thyroid surgery. Future studies should aim to delineate the differences between energy-based haemostasis devices for various indications and surgical techniques, in particular with regard to types and rates of complications, and to determine which instrument is the most costeffective.
